-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRX-3140 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRX-3140 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRX-3140 in Alzheimer's Disease Drug Details:PRX-03140 (NTC-942) is under development for the treatment of Alzheimer's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-501 in Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-501 in Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-501 in Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tobevibart in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tobevibart in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tobevibart in Hepatitis B Drug Details: Tobevibart (VIR-3434) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NTC-011
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NTC-011 Drug Details NTC-011 is under development for the treatment of otitis media and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NTC-801
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NTC-801 Drug Details NTC-801 (BMS-914392) is under development for the treatment of atrial fibrillation...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PRX-3140
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PRX-3140 Drug Details PRX-03140 (NTC-942) is under development for the treatment of Alzheimer's disease. It is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NT-501
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NT-501 Drug Details NT-501 is under development for the treatment of glaucoma and macular...
-
Product Insights
Bacterial Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bacterial Conjunctivitis symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics. The Bacterial Conjunctivitis pipeline drugs market research report provides an analysis of the Bacterial Conjunctivitis drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Blepharitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Blepharitis, an inflammation of the eyelids, occurs with symptoms including watery eyes, red eyes, itchy eyelids, and sensitivity to light. Treatment includes antibiotics, lubricating eye drops, and steroid eye drops or ointments. The Blepharitis pipeline market research report provides an overview of the Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report...
-
Product Insights
Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache, and loss of appetite. Risk factors include age, seasonal factors, and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine. The otitis media drugs in development market research report provides an overview of the Otitis Media pipeline landscape....